Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Solid Biosciences Inc. Director's Dealing 2022

Mar 8, 2022

33003_dirs_2022-03-08_a2e56a7f-312b-421b-8bab-9af93178fe59.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Solid Biosciences Inc. (SLDB)
CIK: 0001707502
Period of Report: 2022-02-10

Reporting Person: Ganot Ilan (Director, CEO & President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-02-10 Common Stock S 463 $1.1202 Disposed 2518 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1202093 Direct
Common Stock 290914 Indirect

Footnotes

F1: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).

F2: Represents 1,141,462 shares held by Mr. Ganot as an individual, and 60,631 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Includes 2,272 shares acquired by Mr. Ganot under the Solid Biosciences Employee Stock Purchase Plan on September 1, 2021.

F3: Represents 290,914 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.